Metotreksat w erozyjnej zapalnej chorobie zwyrodnieniowej stawów rąk (MERINO)
Metotreksat w erozyjnej zapalnej chorobie zwyrodnieniowej stawów (MERINO): randomizowane badanie kontrolowane placebo w celu zbadania skuteczności klinicznej i bezpieczeństwa metotreksatu w erozyjnej zapalnej chorobie zwyrodnieniowej stawów rąk.
A placebo-controlled randomized controlled trial exploring the effect of methotrexate on pain, function and structural outcomes in erosive inflammatory hand osteoarthritis.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
The trial will include Norwegian adult males and females with symptomatic erosive inflammatory hand osteoarthritis.
Participants will be randomized 1:1 to either:
- Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks (intervention group). Dosage can be reduced to as low as 10 mg if higher doses are not tolerated.
- Placebo (control group).
Both arms will receive folic acid 1mg daily.
The treatment duration for both groups is 52 weeks.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Faza 4
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Oslo, Norwegia
- Diakonhjemmet Hospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Finger joint pain 40-80 on 0-100 visual analog scale (VAS) with insufficient pain relief from, inability to tolerate or contra-indications to oral paracetamol and/or NSAIDs, and hand symptoms (pain, aching, or stiffness) on most days the previous 6 weeks before randomization.
- Hand OA according to the American College of Rheumatology (ACR) criteria, at least 1 distal (DIP) or proximal interphalangeal (PIP) joint of the 2nd-5th finger with radiographic pre-erosive (J-phase) or erosive disease (E-phase) according to the Verbruggen-Veys anatomical phase system, and at least two DIP/PIP joints with power Doppler signal of at least grade 1 or grey-scale synovitis of at least grade 2 on ultrasound.
Exclusion Criteria:
A full list of the exclusion criteria for this study comprised the following:
-
Contraindications to methotrexate:
- Abnormal renal function, defined as serum creatinine >142 µmol/L in women and >168 µmol/L in men, or a glomeruli filtration rate (GFR) <40 mL/min/1.73 m2.
- Abnormal liver function, defined as transaminases above the upper normal limit, active or previous hepatitis B or C infection, or known cirrhosis
- Lung fibrosis (maximum 6 months old x-ray), active infection, or reduced hematopoiesis (i.e. anemia, leukopenia and/or thrombocytopenia).
- Planned pregnancy within 18 months after screening (men/women), and pregnancy, breastfeeding, or insufficient anti-conception therapy for female fertile participants. Contraception should be maintained during treatment and until the end of systemic exposure, i.e. 3 months after methotrexate discontinuation. Sufficient anti-conception therapy consists of intra-uterine device (coil) or hormonal anti-conception (birth control pills, implant, intra-uterine system, dermal patch, vaginal ring, or injections).
- Alcohol or other drug abuse in the last year.
- Intolerance to lactose.
-
Chronic inflammatory rheumatic diseases (such as rheumatoid arthritis and psoriatic arthritis or gout), active inflammatory bowel disease, or positive rheumatoid factor or anti-CCP antibodies.
-
Other severe co-morbidities such as hemochromatosis, fibromyalgia, psoriasis, blood dyscrasias, and coagulation disorders, history of malignancy (except successfully treated squamous or basal cell skin carcinoma), uncontrolled diabetes mellitus, severe hypertension, unstable ischemic heart disease, severe heart failure, severe pulmonary disease, severe and/or opportunistic infections and/or chronic infections, active tuberculosis, positive human immunodeficiency virus (HIV) status, recent stroke, bone marrow hypoplasia, or demyelinating diseases of the central nervous system.
-
Other likely causes of hand symptoms: thoracic outlet syndrome, carpal tunnel disease, diabetic cheiropathy, injury in finger joints previous 6 months, or palmar tenosynovitis/trigger finger.
-
Oral or intra-muscular steroids in the previous month
-
Intra-articular treatments or aspirations of any kind of any joint in the hands 3 months before inclusion
-
Analgesics or NSAIDs, unless stable dosage for ≥1 month.
-
Symptomatic slow-acting drugs for OA (SYSADOA), unless stable dose for ≥3 months and require stable dose throughout the study.
-
Disease-modifying osteoarthritis drugs (DMOADs) previous three months.
-
Scheduled hand surgery during study participation.
-
Planning to start other treatments for hand OA in the study participation period.
-
Not able to adhere to the study visit schedule and protocol requirements.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Poczwórny
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Aktywny komparator: Methotrexate
Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks. Additional Folic acid 1mg prescribed daily. |
Methotrexate 2.5mg oral tablet. Folic acid |
|
Komparator placebo: Placebo
3 capsules per week for two weeks, followed by 4 capsules the remaining weeks. Additional Folic acid 1mg prescribed daily. |
Placebo capsule Folic acid |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Finger pain on a visual analogue scale
Ramy czasowe: 6 months
|
Difference in self-reported finger joint pain previous 48 hours on a 0-100 mm scale at 6 months of treatment; higher value indicate worse outcome. |
6 months
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Finger pain on a visual analogue scale
Ramy czasowe: Month 1, 3, 9 and 12.
|
Self-reported finger pain previous 48 hours on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 9 and 12.
|
|
Thumb pain on a visual analogue scale
Ramy czasowe: Month 1, 3, 6, 9 and 12.
|
Self-reported thumb pain previous 48 hours on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
Pain most painful finger joint on a visual analogue scale
Ramy czasowe: Month 1, 3, 6, 9 and 12.
|
Pain most painful finger joint last 48 hours on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
Patient-reported disease activity on a visual analogue scale
Ramy czasowe: Month 1, 3, 6, 9 and 12.
|
Patient-reported disease activity last 48 hours on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
Pain all joints on a visual analogue scale
Ramy czasowe: Month 1, 3, 6, 9 and 12.
|
Pain all joints last 48 hours on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
Hand diagram pain
Ramy czasowe: Month 6.
|
Finger pain and thumb base pain (yes/no) on hand diagram |
Month 6.
|
|
Body diagram pain
Ramy czasowe: Month 6.
|
Pain in other joints (yes/no) on body diagram |
Month 6.
|
|
AUSCAN
Ramy czasowe: Month 1, 3, 6, 9 and 12.
|
Australian/Canadian hand index (AUSCAN), sum score 0-60, higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
OMERACT-OARSI responder criteria
Ramy czasowe: Month 1, 3, 6, 9 and 12.
|
Fulfillment of Outcome Measures in Rheumatology Osteoarthritis Research Society International (OMERACT-OARSI) responder criteria. |
Month 1, 3, 6, 9 and 12.
|
|
EQ-5D
Ramy czasowe: Month 1, 3, 6, 9 and 12.
|
Quality-adjusted life years (QALYs) based on the health-related utility scores measured by the generic instrument EuroQol 5 dimensions (EQ-5D), sum score 5-35, higher value indicate worse outcome, in addition to a 0-100 visual analogue scale where higher value indicate better outcome. |
Month 1, 3, 6, 9 and 12.
|
|
MHOQ
Ramy czasowe: Month 6.
|
Michigan Hand Outcomes Questionnaire (MHOQ) pain and physical function subscales; function subscale range 10-50, higher value indicate worse outcome; task subscale range 17-85, higher value indicate worse outcome; work subscale range 5-25, higher value indicate worse outcome; pain subscale range 10-48, higher value indicate better outcome. |
Month 6.
|
|
Grip strength
Ramy czasowe: Month 1, 3, 6, 9 and 12.
|
Grip strength (in kg; using a hand dynamometer) |
Month 1, 3, 6, 9 and 12.
|
|
HOOS-12
Ramy czasowe: Month 6.
|
Hip disability and Osteoarthritis Outcome Score (HOOS)-12, range 12-60, higher value indicate worse outcome. |
Month 6.
|
|
KOOS-12
Ramy czasowe: Month 6.
|
Knee injury and Osteoarthritis Outcome Score (KOOS)-12, range 12-60, higher value indicate worse outcome. |
Month 6.
|
|
Concomitant medication
Ramy czasowe: Month 1, 3, 6, 9 and 12.
|
Concomitant medication |
Month 1, 3, 6, 9 and 12.
|
|
Tender and swollen joints
Ramy czasowe: Month 1, 3, 6, 9 and 12.
|
Number of tender and swollen joints (range 0-30), higher values indicate more affected joints. |
Month 1, 3, 6, 9 and 12.
|
|
Physician-reported disease activity on a visual analogue scale
Ramy czasowe: Month 1, 3, 6, 9 and 12.
|
Patient-reported disease activity on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
Hand radiographs: Kellgren Lawrence
Ramy czasowe: Month 6 and 12
|
Conventional radiographs: change in radiographic severity according to Kellgren-Lawrence scale, range 0-4 in each joint higher value indicate worse outcome. |
Month 6 and 12
|
|
Hand radiographs: Verbruggen-Veys anatomical phase scoring system
Ramy czasowe: Month 6 and 12
|
Conventional radiographs: radiographic severity in finger joints according to Verbruggen-Veys anatomical phase scoring system, range 1-5; higher value indicate worse outcome. |
Month 6 and 12
|
|
Hand radiographs: OARSI atlas
Ramy czasowe: Month 6 and 12
|
Conventional radiographs: rdiographic severity according to the Osteoarthritis Research Society International (OARSI) atlas for the presence/severity of osteophytes, joint space narrowing and erosions. |
Month 6 and 12
|
|
Hand MRI
Ramy czasowe: Month 6
|
MRI of dominant hand: number of joints with synovitis and BMLs |
Month 6
|
|
Hand ultrasound
Ramy czasowe: Month 1, 3, 6, 9 and 12.
|
Ultrasound: number of finger joints with synovial thickening and power Doppler signals. |
Month 1, 3, 6, 9 and 12.
|
|
Knee ultrasound
Ramy czasowe: Month 6
|
Ultrasound: degree of synovitis in knee joints |
Month 6
|
|
Hip ultrasound
Ramy czasowe: Month 6
|
Ultrasound: degree of synovitis in hip joints |
Month 6
|
|
Adverse events
Ramy czasowe: Through study completion, maximum 12 months, in addition to 3 months after end of treatment.
|
Number of adverse events, serious adverse events, and withdrawals because of adverse events. |
Through study completion, maximum 12 months, in addition to 3 months after end of treatment.
|
Inne miary wyników
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Sub-study: biopsy of knee OA
Ramy czasowe: Month 6
|
Change in synovial cellular composition and gene expression with single-cell RNA sequencing analyses; subgroup analyses, n=16 patients |
Month 6
|
|
Sub-study: knee pain on a visual analogue scale
Ramy czasowe: Month 6
|
Self-reported knee pain previous 48 hours on a 0-100 mm scale at 6 months of treatment; higher value indicate worse outcome. |
Month 6
|
|
Question about blinding
Ramy czasowe: Month 12
|
The participants are asked which treatment they think they have received |
Month 12
|
|
HADS
Ramy czasowe: Month 6
|
Hospital Anxiety and Depression Scales (HADS), range 0-42, higher value indicate worse outcome. |
Month 6
|
|
PCS
Ramy czasowe: Month 6
|
Pain catastrophizing scale, range 0-12, higher value indicate worse outcome. |
Month 6
|
|
PSQ
Ramy czasowe: Month 6
|
Pain Sensitivity Questionnaire (PSQ), range 0-170, higher value indicate worse outcome. |
Month 6
|
|
Anchor questions for MCII and PASS
Ramy czasowe: Month 6
|
Questions about perceived improvement and acceptable symptom state that will be used to define minimally clinically important improvement and patient acceptable symptom state for other questionnaires |
Month 6
|
|
ASES
Ramy czasowe: Month 6
|
Arthritis Self Efficacy Scale (ASES), range 10-100, higher value indicate better outcome. |
Month 6
|
|
Pain sensitization
Ramy czasowe: Month 6
|
Pain sensitization: Pressure Pain Thresholds (PPT) by digital algometer; temporal summation by punctate probes; Conditioned Pain Modulation (CPM) by blood pressure ischemic test. |
Month 6
|
|
Soluble biomarkers of extracellular matrix turnover
Ramy czasowe: Month 6 and 12
|
Markers of collagen degradation (s-COMP, s-C1M, s-C2M, s-C3M, s-CTX1, sHA), collagen synthesis (s-proC2), aggrecan degradation (s-huARGS) and inflammation (s-calprotectin, s- vimentin, s-hsCRP and s-CRPM); Inflammatory cytokines (IL-1β, IL-1ra, IL-4, IL-6, IL-10, IL-12, IL-17, IL-18, IL-21, IFN-γ, TNF-α, VEGF, GM-CSF, CCL2, CCL3, CCL4, CXCL10) and hormones (leptin and resistin). |
Month 6 and 12
|
|
Omics
Ramy czasowe: Month 6 and 12
|
Omics analyses of whole blood |
Month 6 and 12
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Śledczy
Śledczy
- Krzesło do nauki: Tore K Kvien, MD, PhD, Professor Em.
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- DIA2020-01
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
The trialists and other study personnel that conceive of the study, and then plan, manage, monitor, analyze and publish it, will have access to IPD. Participants' identification code numbers are de-identified by replacing the original code number with a new random code number. Only the PI and project coordinator have access to this code.
The protocol, SAP, ICF, and CSR will be shared with regulatory agents as required.
Badanie danych/dokumentów
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .